Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million–